Par for the course where clinical stage biotechs are concerned. We cannot reasonably expect any substantial jumps in revenue, or any net profits unless the vaccine being developed by the NMRC is a winner. So far all signs are positive on this front; we need to be patient and hope for some good news in the next few months.
Ann: Half Yearly Report and Accounts, page-6
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
